company background image
0QT6 logo

Genfit LSE:0QT6 Stock Report

Last Price

€3.32

Market Cap

€165.0m

7D

2.0%

1Y

-8.3%

Updated

27 Mar, 2024

Data

Company Financials +

0QT6 Stock Overview

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases.

0QT6 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for 0QT6 from our risk checks.

Genfit S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Genfit
Historical stock prices
Current Share Price€3.32
52 Week High€4.90
52 Week Low€2.84
Beta0.86
1 Month Change-0.15%
3 Month Change-7.65%
1 Year Change-8.29%
3 Year Change-17.08%
5 Year Change-84.69%
Change since IPO-83.28%

Recent News & Updates

Recent updates

Shareholder Returns

0QT6GB BiotechsGB Market
7D2.0%1.7%2.2%
1Y-8.3%-27.5%3.7%

Return vs Industry: 0QT6 exceeded the UK Biotechs industry which returned -27.5% over the past year.

Return vs Market: 0QT6 underperformed the UK Market which returned 3.7% over the past year.

Price Volatility

Is 0QT6's price volatile compared to industry and market?
0QT6 volatility
0QT6 Average Weekly Movement5.4%
Biotechs Industry Average Movement7.9%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.3%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0QT6 has not had significant price volatility in the past 3 months.

Volatility Over Time: 0QT6's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999154M. Prigenthttps://www.genfit.com

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia.

Genfit S.A. Fundamentals Summary

How do Genfit's earnings and revenue compare to its market cap?
0QT6 fundamental statistics
Market cap€165.04m
Earnings (TTM)-€34.17m
Revenue (TTM)€29.22m

5.6x

P/S Ratio

-4.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QT6 income statement (TTM)
Revenue€29.22m
Cost of Revenue€0
Gross Profit€29.22m
Other Expenses€63.39m
Earnings-€34.17m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Apr 04, 2024

Earnings per share (EPS)-0.69
Gross Margin100.00%
Net Profit Margin-116.97%
Debt/Equity Ratio93.1%

How did 0QT6 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.